Las enfermedades cardiovasculares se presentan del 75 al 80% como causas de morbimortalidad en pacientes con enfermedad renal crónica. En estudios epidemiológicos, las causas más frecuentes de muerte cardiovascular son: muerte súbita, arritmias, falla cardiaca, enfermedad arterial coronaria e infarto del miocardio. La insuficiencia cardiaca y las arritmias cardiacas son causadas por la hipertrofia del ventrículo izquierdo y la fibrosis cardiaca.
Los factores fisiopatológicos involucrados en la hipertrofia del ventrículo izquierdo se dividen en 3 categorías: relacionado a la poscarga, relacionado a la precarga y los no relacionados ni a la poscarga, ni a la precarga.
La hipertrofia miocárdica induce la activación de señales de apoptosis celular y activa las vías metabólicas capaces de aumentar la producción de matriz extracelular hasta fibrosis. La fibrosis conduce al deterioro progresivo de la contractilidad y al engrosamiento de la pared del miocardio, causando disfunción diastólica, sistólica y miocardiopatía dilatada con insuficiencia cardiaca congestiva. El objetivo de esta revisión es conocer la fisiopatología de la hipertrofia del ventrículo izquierdo, de la fibrosis cardiaca y de la disfunción diastólica en la enfermedad renal crónica.
Di Lullo L, Gorini A, Russo D, SantoboniA, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 2015;5:254-226.
Glassock RJ, Pecoits-Filho R, Barbetato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J AM Soc Nephron. 2009;4:S79-S90.
Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia: Beyond coronary heart disease. Semin Dial. 2008;21:308-318.
Ritz E. Left ventricular hypertrophy in renal disease: Beyond preload and afterload. Kidney Int. 2009;75:771-773.
Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol. 1999;31:949-970.
Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, Bache RJ et al. Xanthine oxidase inhibition with ebuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14:746-753.
Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L, Bedja D et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res. 2009;81:301-309.
Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation. 2008;117: 396-404.
Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. Cell Death Differ. 2009;16:31-38.
Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci. 2007;104:16281-16286.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B et al. Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492-1498.
London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.
McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol. 2004;15:1640-1647.
Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR et al. Effect of frequent nocturnal hemodialysis vs. conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA. 2007;298:1291-1299.
Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RS. Defining the natural history of uremic cardiomyopathy in chronic kidney disease. J Am Coll Cardiol Img. 2014;7:703-714.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
Pecoits-Filho R, Bucharles S, Barberato SH. Diastolic heart failure in dyalisis patients: Mechanisms, diagnostic approach and treatment. Seminars in Dialysis. 2012;25(1): 35-41.
Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;298(2):194-202.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-259.
London GM. Left ventricular alterations and endstage renal disease. Nephrol Dial Transplant. 2002;17(suppl 1): 29-36.
Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27(3):347-354.
Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int Suppl. 2003;63(84):S80-83.
Barberato SH, Bucharles SG, Sousa AM, Costantini CO, Costantini CR, Pecoits-Filho R. Prevalence and prognostic impact of diastolic dysfunction in patients with chronic kidney disease in hemodialysis. Arq Bras Cardiol. 2010;94(4):457-462.
Ferreira-Martins J, Leite-Moreira AF. Physiologic basis and pathophysiologic implications of the diastolic properties of the cardiac muscle. J Biomed Biotechnol. 2010;2010:1-12.
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107-133.
Barberato SH, Mantilla DE, Misocami MA, Goncalves SM, Bignelli AT, Riella MC et al. Effect of preload reduction by hemodialysis on left atrial volume and echocardiographic Doppler parameters in patients with end-stage renal disease. Am J Cardiol. 2004;94(9):1208-1210.
Sharma R, Pellerin D, Gaze DC, Mehta RL, Gregson H, Streather CP et al. Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease. J Am Soc Echocardiogr. 2006;19(3):266-273.
Barberato SH, Pecoits-Filho R. Prognostic value of left atrial volume index in hemodialysis patients. Arq Bras Cardiol. 2007;88(6):643-650.
Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539-2550.
Pecoits-Filho R, Barberato SH. Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron Clin Pract. 2010;114(4):c242-c247.
Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009;53(18):1621-1628.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. 2009 focused update incorporated into the ACC ⁄AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation ⁄American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391-e479.